Is Nuvation Bio Stock a Good Investment?
Nuvation Bio Investment Advice | NUVB |
- Examine Nuvation Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Nuvation Bio's leadership team and their track record. Good management can help Nuvation Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Nuvation Bio's business and its evolving consumer preferences.
- Compare Nuvation Bio's performance and market position to its competitors. Analyze how Nuvation Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Nuvation Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Nuvation Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Nuvation Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Nuvation Bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Nuvation Bio Stock
Researching Nuvation Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 27.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.45. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nuvation Bio recorded a loss per share of 2.11. The entity had not issued any dividends in recent years.
To determine if Nuvation Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nuvation Bio's research are outlined below:
| Nuvation Bio generated a negative expected return over the last 90 days | |
| Nuvation Bio has high historical volatility and very poor performance | |
| Nuvation Bio may become a speculative penny stock | |
| The company reported the previous year's revenue of 7.87 M. Net Loss for the year was (567.94 M) with profit before overhead, payroll, taxes, and interest of 795 K. | |
| Nuvation Bio currently holds about 703.8 M in cash with (130.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 59.0% of the company shares are owned by institutional investors |
Nuvation Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nuvation Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nuvation Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Nuvation Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 670.58 M.Basic technical analysis of Nuvation Stock
As of the 21st of March, Nuvation Bio secures the Risk Adjusted Performance of (0.06), mean deviation of 3.29, and Standard Deviation of 5.09. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nuvation Bio, as well as the relationship between them.Nuvation Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nuvation Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nuvation Bio's Outstanding Corporate Bonds
Nuvation Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nuvation Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nuvation bonds can be classified according to their maturity, which is the date when Nuvation Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US67080LAA35 Corp BondUS67080LAA35 | View |
Understand Nuvation Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Nuvation Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.3458 | |||
| Mean Deviation | 3.29 | |||
| Coefficient Of Variation | (1,296) | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.92 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | 0.0124 | |||
| Treynor Ratio | 0.3358 | |||
| Maximum Drawdown | 28.03 | |||
| Value At Risk | (7.38) | |||
| Potential Upside | 6.88 | |||
| Skewness | 1.9 | |||
| Kurtosis | 6.26 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.3458 | |||
| Mean Deviation | 3.29 | |||
| Coefficient Of Variation | (1,296) | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.92 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | 0.0124 | |||
| Treynor Ratio | 0.3358 | |||
| Maximum Drawdown | 28.03 | |||
| Value At Risk | (7.38) | |||
| Potential Upside | 6.88 | |||
| Skewness | 1.9 | |||
| Kurtosis | 6.26 |
Consider Nuvation Bio's intraday indicators
Nuvation Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nuvation Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Nuvation Bio time-series forecasting models is one of many Nuvation Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nuvation Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Nuvation Stock media impact
Far too much social signal, news, headlines, and media speculation about Nuvation Bio that are available to investors today. That information is available publicly through Nuvation media outlets and privately through word of mouth or via Nuvation internal channels. However, regardless of the origin, that massive amount of Nuvation data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nuvation Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nuvation Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nuvation Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nuvation Bio alpha.
Nuvation Bio Corporate Management
| W Vernon | Independent Director | Profile | |
| Michelle Doig | Independent Director | Profile | |
| Gary Hattersley | Chief Scientific Officer | Profile | |
| Moses Makunje | Principal Officer | Profile | |
| Robert Bazemore | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvation Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. If investors know Nuvation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nuvation Bio is measured differently than its book value, which is the value of Nuvation that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvation Bio's value that differs from its market value or its book value, called intrinsic value, which is Nuvation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvation Bio's market value can be influenced by many factors that don't directly affect Nuvation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Nuvation Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Nuvation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.